NCT07204418View on ClinicalTrials.gov

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

December 3, 2026

Study Completion Date

December 3, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

Xanomeline/ Trospium Chloride

Specified dose on specified days

Trial Locations (3)

78209

Local Institution - 0001, San Antonio

92801

Local Institution - 0003, Anaheim

66219-9746

Local Institution - 0002, Lenexa

Sponsors
All Listed Sponsors
lead

Karuna Therapeutics

INDUSTRY

NCT07204418 - A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants | Biotech Hunter | Biotech Hunter